Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study

被引:20
作者
Bogart, Michael [1 ]
Stanford, Richard H. [1 ]
Reinsch, Tyler [1 ,2 ]
Hull, Michael [3 ]
Buikema, Ami [3 ]
Hulbert, Erin [3 ]
机构
[1] US Value Evidence & Outcomes, GSK, 5 Moore Dr, Res Triangle Pk, NC 27709 USA
[2] Univ N Carolina, Div Pharmaceut Outcomes & Policy, 010 Beard Hall,CB 7573, Chapel Hill, NC 27599 USA
[3] Optum LifeSci, Hlth Econ & Outcomes Res, 11000 Optum Circle,MN101-E300, Eden Prairie, MN 55344 USA
关键词
Chronic obstructive pulmonary disease; Triple therapy; Exacerbation; Inhaled corticosteroid; Long-acting muscarinic antagonist; Long-acting beta(2)-agonist; 3-6); OBSTRUCTIVE PULMONARY-DISEASE; BLOOD EOSINOPHILS; PARALLEL-GROUP; DOUBLE-BLIND; EXACERBATIONS; SALMETEROL/FLUTICASONE; RISK;
D O I
10.1016/j.rmed.2018.07.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: This study assessed patient-level characteristics and patterns of medication use in patients with chronic obstructive pulmonary disease (COPD) before initiation of multiple inhaler triple therapy (MITT; long-acing muscarinic antagonist/long-acting beta(2)-agonist/inhaled corticosteroid [ICS/LAMA/LABA] combination). Methods: This retrospective study was conducted using the Optum Research Database. Patients enrolled in commercial or Medicare Advantage Prescription Drug plans, with a COPD diagnosis and > 1 prescription for a COPD medication between January 2014 and March 2016 were included. The dispensing date for the first pharmacy prescription completing MITT with at least 1 day of overlap was the patient's index date. The 12 months prior to this date were used to assess patient characteristics, exacerbations, eosinophil counts and changes in medication. Results: The study population comprised 13,701 patients. At the index date, most patients were using a LAMA (n = 13,353 [97.5%]) and combination ICS/LABA (n = 13,292 [97.0%]) MITT. Overall, 90.4% of patients used a LABA, LAMA, LAMA/LABA, or ICS/LABA or had a moderate or severe exacerbation at any time during the baseline period, indicating that approximately 10% of patients initiated MITT without prior bronchodilator use or exacerbation history. Over 65% of patients with an eosinophil measurement had a value >= 150 cells/mu L. Conclusion: Overall, it appears that in this patient population, ICS/LAMA/LABA as triple therapy is being initiated after use of a bronchodilator and/or after an exacerbation event, in accordance with accepted treatment recommendations.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 35 条
[1]  
Agency for Healthcare Research and Quality (AHRQ), CLIN CLASS SOFTW CCS
[2]  
[Anonymous], 2018, Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis
[3]   Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease A Randomized Placebo-Controlled Trial [J].
Bafadhel, Mona ;
McKenna, Susan ;
Terry, Sarah ;
Mistry, Vijay ;
Pancholi, Mitesh ;
Venge, Per ;
Lomas, David A. ;
Barer, Michael R. ;
Johnston, Sebastian L. ;
Pavord, Ian D. ;
Brightling, Christopher E. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (01) :48-55
[4]  
Brusselle G., 2015, INT J CHRON OBSTRUCT, V10
[5]   Pharmacology and Therapeutics of Bronchodilators [J].
Cazzola, Mario ;
Page, Clive P. ;
Calzetta, Luigino ;
Matera, M. Gabriella .
PHARMACOLOGICAL REVIEWS, 2012, 64 (03) :450-504
[6]  
COPD Foundation, 2017, COPD FDN POCK CONS G
[7]   Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions [J].
Couillard, Simon ;
Larivee, Pierre ;
Courteau, Josiane ;
Vanasse, Alain .
CHEST, 2017, 151 (02) :366-373
[8]  
Davis JR, 2017, AM HEALTH DRUG BENEF, V10, P92
[9]  
Dransfield M.T., 2010, NPJ PRIM CARE RESP M, V20
[10]   Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN studya randomised controlled trial [J].
Frith, Peter A. ;
Thompson, Philip J. ;
Ratnavadivel, Rajeev ;
Chang, Catherina L. ;
Bremner, Peter ;
Day, Peter ;
Frenzel, Christina ;
Kurstjens, Nicol .
THORAX, 2015, 70 (06) :519-527